



Rec'd PCT/PTO

03 MAR 2005
INVESTOR IN PEOPLE**PRIORITY
DOCUMENT**SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 17 NOV 2003


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Dated

3 October 2003

BEST AVAILABLE COPY



The Patent Office

1/77

Request for grant of a patent

See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference P509045GB

6 SEP 2002

2. Patent application number
(The Patent Office will fill in this part)

0220805.6

09SEP02 E746599-8 001038
P01/7700 0.00 0220805.6

3. Full name, address and postcode of the or of each applicant (underline all surnames)

University of Sussex
Falmer
Brighton
BN1 9SB

Patents ADP number (if you know it)

6254866003

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

Peptide Monomers and Protein Structures

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

WITHERS & ROGERS
Goldings House
2 Hays Lane
London
SE1 2HW

Patents ADP number (if you know it)

1776001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant,

YES

or
c) any named applicant is a corporate body.
See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 14

Claim(s) 5

Abstract

Drawing (s) 3 + 3 *SW*

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77) 1

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature W. H. & Rogers Date 6th September 2002

12. Name and daytime telephone number of person to contact in the United Kingdom Adrian Tombling 020 7663 3500

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500 505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

DUPLICATE

P509045GB

Peptide Monomers and Protein Structures

The present invention relates to a fibre-shaping peptides which are capable of interacting with self-assembling peptides to form protein structures. The present invention also relates to methods of forming protein structures using the fibre-shaping peptides of the present invention.

Biological assemblies provide inspiration for the development of new materials for a variety of applications (Holmes, Trends Biotechnol., 20, 16-21, 2002 and Yeates *et al.*, Curr. Opin. Struct. Biol., 12, 464-470, 2002). The ability to realise this potential, however, is hampered by difficulties in producing and engineering natural biomaterials, and in designing them *de novo*. Recently, the inventors described a self-assembling system comprising two short, synthetic polypeptides (dubbed *self-assembling peptides* (also referred to as *straights*) herein), which combine to form extended fibres (see International Patent Application WO 01/21646 and Pandya *et al.*, Biochemistry, 39, 8728-8734, 2000). The fibres described in WO 01/21646 are about 50 nm in diameter, and extend straight and without branching for tens to hundreds of microns. It is desirable to influence and to control fibre morphology.

Previously, the inventors applied the concept of sticky-end directed molecular assembly, which is well documented for the assembly of DNA, to peptides. This led to a self-assembling peptide fibre (SAF) system (Pandya *et al.*, Biochemistry, 39, 8728-8734, 2000). The system comprises two short peptides (SAF-p1 and SAF-p2) of *de novo* design. The SAF-p1 and SAF-p2 sequences were based on accepted design principles for parallel, hetero-dimeric coiled coils, namely leucine zippers (Harbury *et al.*, Science, 262, 1401-1407, 1993; O'Shea *et al.*, Curr. Biol., 3, 658-667, 1993; Woolfson *et al.*, Prot. Sci., 4, 1596-1607, 1995; Ciani *et al.*, J. Biol. Chem., 277, 10150-10155, 2002). However, the SAF peptides were each designed with two distinct regions or subunits: A and B in SAF-p1 and C and D in SAF-p2, respectively; where A complements D and B complements C. Thus, as depicted in Fig. 1a, co-assembly of the two peptides should lead to sticky-ended hetero-dimers, which should further assemble into fibres (see Fig. 1b). These design features were confirmed experimentally using a combination of spectroscopy, X-ray fibre diffraction and microscopy; although, interestingly, the fibres were thicker than originally

anticipated. For instance, transmission electron microscopy (TEM) revealed that, when mixed in water and allowed to mature for short periods, the SAF peptides produced linear structures 40-50 nm in diameter that extended for many microns, Fig. 2a. Except for some rare examples where the fibres were bent, there was no evidence for non-linear or branched structures. More recently, the inventors redesigned SAF-p2 to make SAF-p2a, which combines with SAF-p1 more efficiently and produces fibres with significantly improved stability and internal order compared with the original design; otherwise, the appearance of the matured fibres was not altered.

It would be of considerable interest to alter fibre size and morphology through rational design: for instance, such that specific fibres could be tailored and/or fibre assembly could be made to respond to patterned surfaces, or to cultures of growing cells. One possibility is to introduce *special* peptides (herein referred to as fibre-shaping peptides) that complement and assemble with the *straight* SAF building blocks (self-assembling peptides), but introduce discontinuities into the regularly repeating linear structure.

The present invention provides a fibre-shaping peptide comprising a hub and a plurality of peptide monomer units each being attached at one end thereof to the hub, wherein the free ends of at least 2 peptide monomer units are N-termini or C-termini, and each of the at least 2 peptide monomer units is capable of interacting with a subunit of self-assembling peptide to form an overlapping staggered structure.

The fibre-shaping peptides of the present invention allow morphological changes to be made to protein fibres comprising self-assembling peptides. In particular, the fibre-shaping peptides allow one to incorporate branches, splits, kinks and bends in the protein fibres. By being able to incorporate such morphological changes in the protein fibres it is possible to generate a variety of protein structures, such as assemblies in general, including matrices, filters, networks, grids, scaffolds, etc.

As indicated above, the fibre-shaping peptide of the present invention comprises a hub to which peptide monomer units are attached. The peptide monomer units are attached covalently to the hub. The hub can be any molecule which has at least 2 derivatisable sites (so that it is possible to attach at least 2 peptide monomer units) and which does not

prevent at least 2 peptide monomer units interacting with a sub-unit of a self-assembling peptide to form an overlapping staggered structure. It is further preferred that the hub has more than 2 derivatisable sites enabling the attachment of more than 2 peptide monomer units and/or the attachment of one or more active molecules. It is particularly preferred that the hub has 3 or 4 derivatisable groups.

In a preferred embodiment the fibre-shaping peptide comprises one or more active molecules attached to the hub. The active molecule can be any molecule that has a desired function provided it does not prevent at least 2 peptide monomer units interacting with a sub-unit of a self-assembling peptide to form an overlapping staggered structure. Suitable active molecules include an antibody molecule (i.e. a monoclonal antibody or functional part thereof, including Fab, Fv, F(ab')₂ fragments and single chain Fv fragments), a receptor, a ligand, an enzyme, an antigen, a label, a metal ion or a nucleic acid molecule. The active molecule may be used to bind a desired substance from a solution. For example, an antibody molecule may be used to bind the corresponding antigen. Alternatively, a receptor can be used to bind the corresponding ligand. When the active molecule is a nucleic acid, it can be used to bind transcription factors or even complementary nucleic acids. It is particularly preferred that the active molecule is an RGD based peptide. The RGD peptide can be used to isolate cells from a solution.

The hub is preferably one or more amino acids, more preferably 1 to 6 amino acids and most preferably 1 amino acid. In a preferred embodiment, the hub is lysine. When the hub is lysine, it is possible to attach 2 peptide monomer units via their C-terminus ends to the amino groups. A further peptide monomer unit or an active molecule can be attached to the carboxylic acid group.

In a further preferred embodiment the hub is glutamic acid. When the hub is glutamic acid, it is possible to attach 2 peptide monomer units via their N-terminus ends to the carboxylic acid groups. A further peptide monomer unit or an active molecule can be attached to the amino group.

Preferably the peptide monomer units and the functional molecules are linked to the hub via flexible linkers. The flexible linker may be any suitable linker. Preferably the flexible linker is composed of amino acids such as glycine, serine, alanine and β -alanine. It is particularly preferred that the flexible linker is a poly- β -alanine peptide comprising between 2 and 10 residues, more preferably about 3 to 5 residues. The flexible linker assists in allowing the peptide monomer units to easily interact with the self-assembling peptides and allows any functional molecules to exert their function.

The term "a peptide monomer unit" as used herein refers to a peptide that can interact with a sub-unit of a self-assembling peptide. In other words the peptide monomer unit is complementary to a sub-unit of a self-assembling peptide. The peptide monomer units of the fibre-shaping peptide interact with self-assembling peptides to form overlapping staggered structures which then self-assemble into a protein structure as described in WO 01/21646, and as shown in Figure 1. The sub-unit of the self-assembling peptide is a region that specifically interacts with the peptide monomer unit. Generally, the sub-unit is at one end of the self-assembling peptide to that on interaction an overlapping staggered structure is formed. Preferably the peptide monomer units of the fibre-shaping peptide and the self-assembling peptides comprise a heptad and/or a hendecad repeat motif. It is also preferred that at least one of the peptide monomer units comprises an amino acid residue which is complementary to a residue in a sub-unit of the self-assembling peptide to encourage the fibre-shaping peptide and the self-assembling peptide to form a staggered parallel heterodimer. The amino acid residue in the peptide monomer unit may be any residue which can pair with a complementary amino acid in the sub-unit of the self-assembling peptide. Preferably the complementary amino acids are pairs of asparagines, arginines or lysines. It is also preferred that the complementary amino acids are at interfacial sites on the peptides. Preferably the complementary amino acids are in the "a" position within the heptad or hendecad repeat motif on the peptide monomer unit and in the sub-unit of the self-assembling peptide.

The fibre-shaping peptide of the present invention may comprise more than 2 peptide monomer units. It is preferred that the fibre-shaping peptide comprises 2 to 10 peptide monomer units, more preferably 2 to 5 peptide monomer units, most preferably 2 peptide

monomer units. As indicated above, the number of peptide monomer units in the fibre-shaping peptide will depend on the number of derivatisable groups on the hub.

As indicated above, at least 2 of the peptide monomer units must have either free N-terminal ends or free C-terminal ends. By ensuring that the fibre-shaping peptide comprises 2 peptide monomer units having the same free ends (i.e. both C-terminal or both N-terminal ends), 2 self-assembling peptides are forced to converge leading to a discontinuity in the protein structure formed by the self-assembling peptides (see Figure 1c and d).

The term "self-assembling peptide" as used herein refers to a peptide that can interact with other self-assembling peptides to form a substantially linear structure, preferably a straight protein fibre. The self-assembling peptides preferably associate in a parallel and contiguous manner. Suitable self-assembling peptides are described in WO 01/21646. Preferably the self-assembling peptide comprises a heptad or hendecad repeat motif, wherein a pair of complementary amino acids residues on different self-assembling peptides encourage the self-assembling peptides to form a staggered parallel heterodimer coiled-coil. The complementary amino acid residues may be any residues which can form a pair. Preferably the complementary amino acids are pairs of asparagines, arginines or lysines. It is also preferred that the complementary amino acids are at interfacial sites on the peptides. Preferably the complementary amino acids are in the "a" position within the heptad or hendecad repeat motif in the self-assembling peptide.

It is particularly preferred that the self-assembling peptide has the sequence

NH₃-KIAALKQKIASLKQEIDALEYENDALEQ-COOH (SAF-p1)

or the sequence

NH₃-KIRRLKQKNARLKQEIAALEYEIAALEQ-COOH (SAF-p2a).

The present invention also provides a self-assembling peptide having the sequence

NH₃-KIRRLKQKNARLKQEIAALEYEIAALEQ-COOH (SAF-p2a).

The standard single letter amino acid terminology is used in the sequences given in the present application.


The term "overhanging staggered structure" refers to a structure in which 2 peptides assemble to form a heterodimer having overhanging ends that are not interacting within the heterodimer.

The peptides of the present invention, including the fibre-shaping peptides and the self-assembling peptides are preferably between 15 and 100 amino acids in length, more preferably between 20 and 50 amino acids in length, most preferably about 30 amino acids in length. The peptides may comprise naturally occurring amino acids, synthetic amino acids and naturally occurring amino acids that have been modified.


The term "fibre" as used herein refers to a protein structure assembled from overlapping staggered structures interacting through the overhanging ends. A number of fibres may interact laterally thereby forming thicker fibres. It is particularly preferred that the term refers to a hetero-dimeric coiled coil structure.

The term "amino acid" as used herein refers to naturally occurring amino acids, synthetic amino acids and naturally occurring amino acids that have been modified.

In a particularly preferred embodiment of the present invention the fibre-shaping peptide of the present invention has the formula:



or



wherein abcdefg is a heptad repeat motif;

X is a flexible linker;

Y is a hub;

Z is a functional molecule;

q is 1 to 15;

m is 0 or 1;

n is 2 to 10; and
 p is 0 to 4.

Preferably, X is a flexible linker as defined above.

Preferably Y is lysine in formula (I).

Preferably Y is glutamic acid in formula (II).

Preferably q is 1 to 5.

Preferably n is 2.

The present invention also provides a fibre-shaping peptide having the sequence:



The present invention also provides a fibre-shaping peptide having the sequence:



βA as used in the above sequences represents β -alanine.

The present invention also provides a protein structure comprising the fibre-shaping peptide of the present invention.

Preferably the protein structure comprises a plurality of fibre-shaping peptides according to the present invention and a plurality of self-assembling peptides as defined above which can self-assemble to form a linear protein structure, wherein the fibre-shaping peptides and the self-assembling peptides self-assemble to form a protein structure.

As will be appreciated by those skilled in the art, in order to form a protein structure the plurality for self-assembling peptides will comprise a first set of self-assembling and a second set of self-assembly fibres which interact to form a substantially linear structure. Preferably, the ratio of fibre-shaping peptides: first self-assembly peptides: second

self-assembly peptides comprised in the protein structure of the present invention is from about 1×10^{-6} :1:1 to 10:1:1, more preferably from about 1×10^{-4} :1:1 to 2:1:1.

The term "protein structure" refers to any combination of secondary protein structures, such as helices and β strands. It is particularly preferred that the protein structure is or comprises one or more protein fibres, wherein the protein fibres are as defined above.

Preferably the protein structure of the present invention comprises kinked and waved fibres.

Preferably the protein structure of the present invention comprises split and branched fibres.

The present invention also provides a method for producing the protein structure of the present invention, comprising mixing a plurality of fibre-shaping peptides of the present invention and a plurality of self-assembling peptides under conditions so that the peptides associate to form a protein structure.

Suitable conditions for forming a protein structure by mixing the peptides will be apparent to those skilled in the art, especially in view of the information given in WO 01/21646.

The present invention also provides a kit for producing the protein structure of the present invention, wherein the kit comprises a plurality of the fibre-shaping peptides of the present invention and a plurality of self-assembling peptides, wherein the fibre-shaping peptides and the self-assembling peptides can associate to form a protein structure.

By controlling the amount of fibre-shaping peptides in the protein structure, the morphology of the protein structure can be changed. Accordingly, it is possible to have some control over the protein structures being generated. In particular, protein fibres can be arranged to form 2 and 3 dimensional assemblies such as grids, scaffolds, filters, networks and matrices. Such protein structures can be used in a number of applications such as in the purification of biological fluids such as blood, or the assembly of cells for

cell and tissue engineering purposes. The protein structures may also be used for surface engineering (see Zhang *et al.*, Biomaterials, 16, 1385-1393, 1995).

Furthermore, as the fibre-shaping peptides can comprise functional molecules the protein structure can be functionalised. For example, if the functional molecules are capable of specifically binding a desired component or contaminant, the matrix can be used as an affinity matrix for isolating a desired component or for removing a contaminant. For example in the case of virus removal from a blood sample, a binder for the target contaminant (e.g a peptide or protein with natural or engineered affinities for a viral coat protein) is the functional molecule attached to the fibre-shaping peptide. The matrix can then be removed from blood along with any bound contaminants by light centrifugation.

The protein structures of the present application have a number of other applications including:

- i. preparation of organised networks for seeding the crystallisation of biomolecules for X-ray crystallography;
- ii. using protein structures to promote cell growth for tissue engineering;
- iii. the construction of nanoscale molecular sieves and other devices;
- iv. the preparation of nanoscale molecular grids/scaffolds that could be used as supports for a variety of functional molecules;
- v. functionalised protein structures could be used in, for example, catalysis, affinity-sieving/purification of biological fluids and other research solutions, the recruitment of endogenous molecules and co-factors to promote tissue repair and tissue engineering in general.

Although the fibre-shaping peptide of the present invention may comprise one or more functional molecules, additional functional molecules can be attached to the protein structure of the present invention at any appropriate site using standard coupling techniques.

The present invention is now described, by way of example only, with reference to the accompanying Figures.

Figure 1 illustrates the design principles and sequences for the self-assembling fibre (SAF) and fibre-shaping (FiSh) peptides: **a**. The standard SAF peptide sequences each shown divided into two blocks: A and B for SAF-p1; C and D for SAF-p2a. **a & b**. Block A complements D and B complements C. This leads to sticky-ended dimers that assemble further into fibres. The register of the assembly is partly maintained by the key asparagine residues highlighted by the asterisks. **c & d**, The discontinuities designed to be introduced by the FiSh peptides CC^{NN} and DD^{CC}, respectively. In **b**, **c** & **d**, the direction of the polypeptide chain (N- to the C-termini) is shown by the arrowheads. This relates to the nomenclature of the FiSh peptides; for example, CC^{NN} is so-named because it comprises two copies of the block C from SAF-p2a linked through their C-termini, which leaves both N-termini free at the ends of the construct. The FiSh peptides are shown kinked rather than straight as the linkers contain flexible b-alanine residues.

Figure 2 shows uranyl-acetate stained TEM images of fibres formed from the SAF and SAF-FiSh systems. **a**, straight fibres formed from mixing SAF-p1 and SAF-p2a in a 1:1 ratio. **b-d**, kinked and waved fibres formed by adding the CC^{NN} FiSh peptide to fresh SAF-p1/SAF-p2a mixtures in 1:1:1 (**b**), 0.1:1:1 (**c**), and <0.1:1:1 (**d**) (FiSh:SAF-p1:SAF-p2a) ratios. **e&f**, split and branched (bounded by the box in **f**) fibres formed by adding the DD^{CC} FiSh peptide to fresh SAF-p1/SAF-p2a mixtures in 0.01:1:1 ratios.

Figure 3 shows the results of an analysis of the morphological changes introduced into the self-assembling fibres: **a**, shows the average number of features (kinks or splits) per 10 μm length of fibres. **b**, shows the average length of the mature fibres as functions of the ratio of FiSh to SAF peptides. Data points for CC^{NN}-containing fibres are shown as circles, whereas those for DD^{CC}-containing fibres are shown as squares. In panel **a** the numbers of kinks and splits produced by DD^{CC} are distinguished by solid and broken lines, respectively. Analysis: the numbers given are averages measured over 80-100 fibres. Standard deviations on the measurements in **a** were: 2.6 (for 0.01:1:1) and 0.2 (for <0.01:1:1) for the CC^{NN}-containing fibres; 0.4 (for 0.01:1:1) and 0.1 (for <0.01:1:1) for the DD^{CC}-containing split fibres, and 0.4 (for 0.01:1:1) and 0.1 for (>0.01:1:1) for the kinked

fibres. Standard deviations on the measurements in **b** were 5.6 μm (for 0.01:1:1) and 1.6 μm (for >0.01:1:1) for data from both FiSh peptides.

EXAMPLES

Materials and Methods

PEPTIDE SYNTHESIS

Peptides were synthesized using standard solid-phase Fmoc chemistry, purified by RP-HPLC and confirmed by MALDI-TOF mass spectrometry.

FIBRE ASSEMBLY

All samples of fibres were prepared with SAF-p1 and SAF-p2a (each at 100 μM concentration) with the designated amounts of FiSh peptides, and incubated at 22 °C overnight following the techniques described in Pandya *et al.*, 2000 (*supra*).

ELECTRON MICROSCOPY

Fibre suspensions were dried onto carbon grids and stained with uranyl acetate for electron microscopy as described previously in Pandya *et al.*, 2000 (*supra*).

The novel protein structures described herein were made by combining SAF-p1 and SAF-p2a in the presence of fibre-shaping peptides based on the SAF-p2a sequence following the technique described in Pandya *et al.*, 2000 (*supra*).

The present invention is demonstrated, by way of example only, with two novel peptides, CC^{NN} and DD^{CC}, which introduce kinks/waves and splits/branches into the SAF fibres, respectively.

The design principles for CC^{NN} and DD^{CC} peptides are shown schematically in Figs. 1c&d. The peptides were based on the SAF-p2a sequence, Fig. 1a. For example, in CC^{NN} the N-terminal "C" subunit of SAF-p2a was duplicated in a tail-to-tail fashion; *i.e.*, two copies of the C sequence (hence the "CC" term) were linked through their C-termini leaving the N-termini free at the ends of the construct (hence the "NN" superscript). This was

achieved by synthesising two C subunits simultaneously from the two amino groups of a single, bifunctional hub, namely L-lysine attached via its carboxy terminus to a solid-phase peptide synthesis resin. To allow additional flexibility at the lysine joint, three β -alanine monomers were added to the amino groups of the lysine prior to synthesis of the C sequences. As depicted in Fig. 1c, this should set up the possibility for CC^{NN} to interact with two copies of SAF-p1. However, this interaction is altogether different from the interaction originally prescribed for the self-assembling peptides (*straights*), SAF-p2a and SAF-p1: the association of these is parallel and contiguous, Figs. 1a&b, which leads to linear and potentially infinite assemblies (Pandya *et al.*, Biochemistry, 39, 8728-8734, 2000); in contrast, the addition of CC^{NN} aimed to force two neighbouring SAF-p1 peptides to converge; the reason for including the β -alanine linker was thus to accommodate any resulting discontinuity and, so, effectively allow fibrillogenesis from the two SAF-p1 peptides, Fig. 1c. Similar principles were used in the DD^{CC} design except that two copies of the D subunit of SAF-p2a were linked through their N-termini using L-glutamic acid as a hub, Fig. 1d; again three β -alanine residues were used to separate each of the D peptide sequences from the hub. There are subtle differences in the sequences of the C and D units, Fig. 1a, which, as discussed below, resulted in different morphological changes in the SAF assemblies.

Consistent with the design, when CC^{NN} was doped into a fresh SAF-p1/SAF-p2a mixture the resulting matured fibres were not straight, but kinked or wavy, Figs 2b,c&d. Varying the ratio of CC^{NN} in the starting mixtures altered the numbers of kinks per unit length of fibres, Fig. 3a. However, this was at the expense of fibre integrity: the inclusion of more CC^{NN} reduced the length of the fibres that were formed, Fig. 3b. Though some linear fibres were observed these were rare, and the number reduced rapidly with increasing amounts of CC^{NN} .

Intriguingly, inclusion of DD^{CC} in fresh SAF-p1/SAF-p2a mixtures led to two different morphologies in the matured fibres: with small amounts of the FiSh peptide (10^{-4} :1:1 of DD^{CC} :SAF-p1:SAFp2a) the fibres kinked as observed with CC^{NN} . However, as the ratio of DD^{CC} was increased (up to 1:1:1) less kinking was observed, and instead the fibres tended to split or branch, Figs. 2e&f and Fig. 3a.

The difference in behaviour of the two FiSh peptides must result from the different sequences of the C and the D subunits, Fig. 1a. In the original SAF design, the C subunit of SAF-p2 was made to partner the B subunit of SAF-p1 specifically by the inclusion of complementary asparagine residues in each of the peptides at a key interfacial site (Pandya *et al.*, *Biochemistry*, 39, 8728-8734, 2000); this feature was preserved in the SAF-p2a design. This is a so-called negative-design principle (Beasley *et al.*, *J. Biol. Chem.*, 277, 10150-10155, 2002); that is, it is a feature incorporated to direct the assembly of one structure and guard against the formation of potential alternatives. In the case of the SAFs, the asparagine residues were included to ensure parallel heterodimer formation (Harbury *et al.*, *Science*, 262, 1401-1407, 1993, O'Shea *et al.*, *Curr. Biol.*, 3, 658-667, 1993, Woolfson *et al.*, *Prot. Sci.*, 4, 1596-1607, 1995, O'Shea *et al.*, *Science*, 254, 539-44, 1991, Lumb *et al.*, *Biochemistry*, 34, 8642-8648, 1995 and Gonzalez *et al.*, *Nature Struct. Biol.*, 3, 1011-1018, 1996) to offset the register of the two peptides and hence to promote fibrillogenesis (Pandya *et al.*, *Biochemistry*, 38, 8728-8734, 2000). Although the inclusion of asparagine increases dimer and register specificity in leucine-zipper peptides this is at the expense of overall stability (Harbury *et al.*, *Science*, 262, 1401-1407, 1993, Lumb *et al.*, *Biochemistry*, 34, 8642-8648, 1995 and Gonzalez *et al.*, *Nature Struct. Biol.*, 3, 1011-1018, 1996). The CC^{NN} peptide has two such asparagines and the DD^{CC} has none. Therefore, the inventors suspect that the DD^{CC} forms stronger leucine-zipper interactions and is potentially the more promiscuous in its interactions with the standard SAF peptides, and that this leads to split and/or thickened appearance of some of the fibres, Fig. 2e&f. Put another way, CC^{NN} is more selective in the interactions it makes. This, combined with the presumed lower stability of B:C interactions compared with A:D interactions, leads to fewer and more-easily rectified imperfections (such as splitting and thickening).

Following the scheme of Fig. 1, there are sixteen possible combinations of the C and D subunits of SAF-p2a. We synthesised two of these, CD^{NC} and CC^{NC}, as control peptides. CD^{NC} was simply the SAF-p2a sequence with a spacer inserted between the C and D subunits; in CC^{NC} two successive copies of C were separated by the spacer; in both cases the spacer comprised three β -alanine residues, a central ϵ -aminohexanoic acid residue (as a substitute for the L-lysine and L-glutamic acid hubs used in CC^{NN} and DD^{CC}), followed by three further β -alanine residues. Neither CD^{NC} nor CC^{NC} caused kinking, waving, splitting or branching of the matured fibres as observed for CC^{NN} and DD^{CC}. However, at ratios of

10⁻²:1:1 (control:SAF-p1:SAF-p2a) and above, both CD^{NC} and CC^{NC} inhibited fibre assembly completely; mixtures with smaller amounts of control peptide did produce fibres, but these were short (<20 mm) and rare (500 times less abundant than in mixtures containing the FiSh peptides CC^{NN} and DD^{CC}). In other words, CD^{NC} and CC^{NC} acted as terminators in fibrillogenesis.

In summary, the inventors have presented experimental data for altering the shapes of designed self-assembly fibres that originally formed exclusively linear and non-branched structures. Fibre-shaping (FiSh) peptides were added to mixtures of peptides that would otherwise have formed linear assemblies. The two FiSh peptides tested influenced fibres morphology differently: one kinked the fibres, whereas the other split, or branched them. The ratio of FiSh to standards peptide determined the number of kinked and branched features observed.

The ability to alter fibre morphologies can be used in the development of biomaterials that respond to cues provided by their environment. Such cues might be presented as a pattern on a surface. This could lead to surfaces functionalised with proteins for the applications in protein-array technology and the development of new protein-based diagnostic/sensor devices. Another possibility is for the assembly of networks that might be used as scaffolds in cell and tissue engineering. In this case the self-assembly fibres could be induced to respond to, and so support cell growth.


As indicated above, as the FiSh peptides may comprise other functional molecules. In this way the FiSh peptides could be used to recruit bioactive peptides, proteins and small molecules to assembled fibres. For example, the additional moiety could be a peptide antigen, which once incorporated into the fibre could be used to pull-down (*i.e.* recruit) a specific antibody to the fibre surface. Alternatively, if the functional molecule is a nucleic acid sequence, transcription factors that interact with the nucleic acid sequence may be isolated. In these respects, the FiSh peptides should be considered as *nodes* at which functional groups could be located.

All documents cited above, are incorporated herein by reference.

Claims

1. A fibre-shaping peptide comprising a hub and a plurality of peptide monomer units each being attached at one end thereof to the hub, wherein the free ends of at least 2 peptide monomer units are N-termini or C-termini, and each of the at least 2 peptide monomer units is capable of interacting with part of a self-assembling peptide to form an overlapping staggered structure.
2. The fibre-shaping peptide according to claim 1, wherein the hub is one or more amino acids residue having a plurality of derivatisable sites to which the peptide monomer units can be attached.
3. The fibre-shaping peptide according to claim 2, wherein the hub is lysine or glutamic acid.
4. The fibre-shaping peptide according to any one of the preceding claims, which comprises 2 to 4 peptide monomer units.
5. The fibre-shaping peptide according to any one of claims 1 to 3, which comprises 2 peptide monomer units.
6. The fibre-shaping peptide according to any one of the preceding claims, wherein each peptide monomer unit is attached to the hub via a flexible linker.
7. The fibre-shaping peptide according to claim 6, wherein the flexible linker is a peptide linker comprises amino acids selected from the group consisting of glycine, alanine, serine and β -alanine.
8. The fibre-shaping peptide according to claim 6, wherein the flexible linker is a poly- β -alanine peptide.

9. The fibre-shaping peptide according to any one of the preceding claims which additionally comprises one or more functional molecules attached to the hub.
10. The fibre-shaping peptide according to claim 9, wherein the functional molecule is an antibody molecule, a receptor, a ligand, an enzyme, an antigen, a label, a metal ion or a nucleic acid molecule.
11. The fibre-shaping peptide according to claim 9 or claim 10, wherein the functional molecule is attached to the hub via a flexible linker.
12. The fibre-shaping peptide according to claim 11, wherein the flexible linker is a peptide linker comprises amino acids selected from the group consisting of glycine, alanine, serine and β -alanine.
13. The fibre-shaping peptide according to claim 11, wherein the flexible linker is a poly- β -alanine peptide.
14. The fibre-shaping peptide according to any one of the preceding claims, wherein the at least 2 peptide monomer units comprise a heptad repeat motif and/or a hendecad repeat motif.
15. The fibre-shaping peptide according to claim 14, which is capable of forming a staggered parallel coiled coil structure with a self-assembling peptide which comprises a heptad repeat motif and/or a hendecad repeat motif.
16. The fibre-shaping peptide according to claim 1 having the formula:



or



wherein abcdefg is a heptad repeat motif;

X is a flexible linker;

Y is a hub;

Z is a functional molecule;

q is 2 to 15;

m is 0 or 1;

n is 2 to 4; and

p is 1 to 4.

17. The fibre-shaping peptide according to claim 16, wherein X is a poly- β -alanine peptide.

18. The fibre-shaping peptide according to claim 16 or claim 17, wherein Y is lysine in formula (I).

19. The fibre-shaping peptide according to claim 16 or claim 17, wherein Y is glutamic acid in formula (II).

20. The fibre-shaping peptide according to any one of claims 16 to 19, wherein q is 1 to 5.

21. The fibre-shaping peptide according to any one of claims 16 to 20, wherein n is 2.

22. A fibre-shaping peptide having the sequence:



23. A fibre-shaping peptide having the sequence:




24. A protein structure comprising a fibre-shaping peptide according to any one of the preceding claims.

25. A protein structure comprising a plurality of fibre-shaping peptides according to any one of claims 1 to 23 and a plurality of self-assembling peptides, wherein the first and second peptide monomers self-assemble to form a non-linear protein structure.
26. The protein structure according to claim 23, wherein the ratio of fibre-shaping peptides: first self-assembling peptides: second self-assembling peptides is from about 1×10^{-6} :1:1 to 10:1:1.
27. The protein structure according to claim 25, which comprises kinked and waved protein fibres.
28. The protein structure according to claim 25, which comprises split and branched protein fibres.
29. The protein structure according to claim 25, which is a matrix, a grid, a scaffold, a filter or a network.
30. The protein structure according to any one of claims 25 to 29, wherein the plurality of self-assembling peptides comprises peptides having the sequence $\text{NH}_3\text{-KIAALKQKIASLKQEIDALEYENDALEQ-COOH}$ and peptides having the sequence $\text{NH}_3\text{-IRRLKQKNARLKQEIAALEYEIAALEQ-COOH}$.
31. A method of producing a protein structure according to any one of claims 25 to 30, comprising mixing a plurality of fibre-shaping peptides according to any one of claims 1 to 23 and a plurality of self-assembling peptides under conditions so that the peptides associate to form a protein structure.
32. A kit for producing a protein structure according to any one of claims 25 to 30, wherein the kit comprises a plurality of fibre-shaping peptides according to any one of claims 1 to 23 and a plurality of self-assembling peptides which, wherein the first and second peptide monomers can associate to form a protein structure.


33. Use of the protein structure according to any one of claims 24 to 30 in the purification of biological fluids.
34. Use of the protein structure according to any one of claims 24 to 30 for assembling cells for cell and tissue engineering.
35. Use of the protein structure according to any one of claims 24 to 30 in surface engineering procedures.
36. A self-assembling peptide having the sequence
NH₃-KIRRLKQKNARLKQEIAALEYEIAALEQ-COOH (SAF-p2a).

Figure 1


a



b



c



d




Figure 2




Figure 3

